Asbestos-induced chronic inflammation in malignant pleural mesothelioma and related therapeutic approaches—a narrative review
Open accessThe DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Abstract
Objective: The aim of this review is addressing the mechanisms of asbestos carcinogenesis, including chronic inflammation and autophagy-mediated cell survival, and propose potential innovative therapeutic targets to prevent mesothelioma development or improve drug efficacy by reducing inflammation and autophagy. Background: Diffuse malignant pleural mesothelioma is an aggressive cancer predominantly related to chronic inflammation caused by asbestos exposure. Millions of individuals have been exposed to asbestos or to other carcinogenic mineral fibers occupationally or environmentally, resulting in an increased risk of developing mesothelioma. Overall patient survival rates are notably low (about 8–14 months from the time of diagnosis) and mesothelioma is resistant to existing therapies. Additionally, individuals carrying inactivating germline mutations in the BRCA-associated protein 1 (BAP1) gene and other genes are predisposed to developing cancers, prevalently mesothelioma. Their risk of developing mesothelioma further increases upon exposure to asbestos. Recent studies have revealed the mechanisms and the role of inflammation in asbestos carcinogenesis. Biomarkers for asbestos exposure and malignant mesothelioma have also been identified. These findings are leading to the development of novel therapeutic approaches to prevent or delay the growth of mesothelioma. Methods: Review of full length manuscripts published in English from January 1980 to February 2021 gathered from PubMed.gov from the National Center of Biotechnology Information and the National Library of Medicine were used to inform this review. Conclusions: Key regulators of chronic inflammation mediate asbestos-driven mesothelial cell transformation and survival through autophagic pathways. Recent studies have elucidated some of the key mechanisms involved in asbestos-induced chronic inflammation, which are largely driven by extracellular high mobility group box 1 (HMGB1). Upon asbestos exposure, mesothelial cells release HMGB1 from the nucleus to the cytoplasm and extracellular space, where HMGB1 initiates an inflammatory response. HMGB1 translocation and release also activates autophagy and other pro-survival mechanisms, which promotes mesothelioma development. HMGB1 is currently being investigated as a biomarker to detect asbestos exposure and to detect mesothelioma development in its early stage when therapy is more effective. In parallel, several approaches inhibiting HMGB1 activities have been studied and have shown promising results. Moreover, additional cytokines, such as IL-1β and TNF-α are being targeted to interfere with the inflammatory process that drives mesothelioma growth. Developing early detection methods and novel therapeutic strategies is crucial to prolong overall survival of patients with mesothelioma. Novel therapies targeting regulators of asbestos-induced inflammation to reduce mesothelioma growth may lead to clinical advancements to benefit patients with mesothelioma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In turn, HMGB1 and pro-inflammatory cytokines promote the recruitment of macrophages and, together with ROS, sustain the chronic inflammatory process and DNA damage leading to mesothelial cell transformation over the years [1,21].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Molecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091 · cited 1×
“EMT is an essential pathogenic process in tumor progression allowing epithelial cells to acquire characteristics of mesenchymal cells (26).”
BackgroundYang, Y., Li, S., Yang, Q., Shi, Y., Zheng, M., Liu, Y., Chen, F., Song, G., Xu, H., Wan, T., et al. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000358696 · Cited by 3,253
Innate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica
Dostert, C., Pétrilli, V., Van Bruggen, R., Steele, C., Mossman, B. T., & Tschopp, J. (2008) · Science · doi:10.1126/science.1156995 · Cited by 2,658
A novel heterodimeric cysteine protease is required for interleukin-1βprocessing in monocytes
Thornberry, N. A., Bull, H. G., Calaycay, J. R., Chapman, K. T., Howard, A. D., Kostura, M. J., Miller, D. K., Molineaux, S. M., Weidner, J. R., Aunins, J., et al. (1992) · Nature · doi:10.1038/356768a0 · Cited by 2,572 · cited 1×
“The activated NLRP3 inflammasome controls and promotes the secretion of IL-1β and IL-18 by caspase-1 cleaving pro-IL-1β and pro-IL-18 to their mature forms (50,51).”
BackgroundTreating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,768
Molecular mechanisms regulating NLRP3 inflammasome activation
Jo, E.-K., Kim, J. K., Shin, D.-M., & Sasakawa, C. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.95 · Cited by 1,378
The role for autophagy in cancer
White, E. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73941 · Cited by 1,332
Baas, P., Scherpereel, A., Nowak, A. K., Fujimoto, N., Peters, S., Tsao, A. S., Mansfield, A. S., Popat, S., Jahan, T., Antonia, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32714-8 · Cited by 1,215
Reversing established sepsis with antagonists of endogenous high-mobility group box 1
Yang, H., Ochani, M., Li, J., Qiang, X., Tanovic, M., Harris, H. E., Susarla, S. M., Ulloa, L., Wang, H., DiRaimo, R., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2434651100 · Cited by 1,126
Self-citation
Research works printed but not linked: 1
- [80]Jube SL, Rivera Z, Casalgrandi M, BoxA and ethyl pyruvate offer novel therapeutic approaches for human malignant mesothelioma. Cancer Res 2013; 73: 5557.
Cited by
Pyroptosis in inflammatory diseases and cancer
Rao, Z., Zhu, Y., Yang, P., Chen, Z., Xia, Y., Qiao, C., Liu, W., Deng, H., Li, J., Ning, P., et al. (2022) · Theranostics · doi:10.7150/thno.71086 · Cited by 800
“Chronic inflammation and pyroptosis also involves the development of asbestos-associated mesothelioma [105].”
BackgroundMangiante, L., Alcala, N., Sexton‐Oates, A., Genova, A. D., González-Pérez, A., Khandekar, A., Bergstrom, E. N., Kim, J., Liu, X., Blázquez‐Encinas, R., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01321-1 · Cited by 103
Nthunya, L. N., Mosai, A. K., López‐Maldonado, E. A., Bopape, M. F., Dhibar, S., Nuapia, Y. B., Ajiboye, T. O., Buledi, J. A., Solangi, A. R., Sherazi, S. T. H., et al. (2025) · Chemosphere · doi:10.1016/j.chemosphere.2025.144470 · Cited by 60
Fiorilla, I., Martinotti, S., Todesco, A. M., Bonsignore, G., Cavaletto, M., Patrone, M., Ranzato, E., & Audrito, V. (2023) · Cells · doi:10.3390/cells12162048 · Cited by 39
Fennell, D. A., Sekido, Y., Baas, P., Husain, A. N., Fontecedro, A. C., Lim, E. K. S., Opitz, I., Simone, C. B., Brims, F., & Wong, M. C. S. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00640-3 · Cited by 47
“Asbestos fibres travelling to and deposited in the visceral pleura pro mote chronic inflammation 68 , which can induce mesothelioma 32 .”
Metadata
- Authors
- Zolondick, A. A., Gaudino, G., Xue, J., Pass, H. I., Carbone, M., & Yang, H.
- Affiliations
- University of Hawaiʻi at Mānoa (US)
- University of Hawaii Cancer Center (US)
- NYU Langone Health (US)
- Corresponding author
- Yang, Haining
- Venue
- Precision Cancer Medicine
- Publisher
- AME Publishing Company
- Published
- 2021-09
- Volume
- 4
- Pages
- 27-27
- ISSN
- 2617-2216 (ISSN-L)
- PMC
- PMC8797751
- OpenAlex
- W3191102673
- Cited by
- 41
- References
- 107
- Citations by year
- 2026: 4 · 2025: 16 · 2024: 7 · 2023: 9 · 2022: 5
- FWCI
- 0.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Precision Cancer Medicine (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nc-nd)
- Funders
- National Institutes of Health (5r01ca237235-05)
- National Cancer Institute (R01CA160715, U01CA214195, R01 CA237235)
- National Institute of Environmental Health Sciences (R01ES030948)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Social Sciences › Health › Occupational Health and Global Justice
- Keywords
- malignant pleural mesothelioma, asbestos exposure, asbestos carcinogenesis, chronic inflammation, autophagy, HMGB1, BAP1 mutation, IL-1β, TNF-α, anti-inflammatory therapy, early detection, therapeutic target, occupational exposure, mineral fibers, cancer susceptibility
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Asbestos-induced chronic inflammation in malignant pleural mesothelioma and related therapeutic approaches—a narrative review. https://app.cochat.ai/papers/10.21037/pcm-21-12
- The paper
- Zolondick, A. A., Gaudino, G., Xue, J., Pass, H. I., Carbone, M., & Yang, H. (2021). Asbestos-induced chronic inflammation in malignant pleural mesothelioma and related therapeutic approaches—a narrative review. Precision Cancer Medicine. https://doi.org/10.21037/pcm-21-12
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.